Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose nearly 3%, and total revenue for the third quarter reached US$108.2 million and is expected to submit ZOCI's first BLA in the US next year

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose nearly 3%. As of press release, it had risen 2.59% to HK$18.64, with a turnover of HK$30.124 million.

According to the news, on November 5, Zaiding Pharmaceutical announced that the total revenue for the third quarter of 2026 was US$108.2 million, compared to US$116.1 million for the same period in 2025. Net product revenue for the third quarter of 2026 was US$107.6 million, compared to US$115.4 million for the same period in 2025. Dr. Du Ying, founder, chairman and CEO of Zaiding Pharmaceutical, said that the strong data on Zoci first-line combination therapy announced at the ESMO conference strengthened the company's confidence that it is expected to become the preferred cornerstone ADC for small cell lung cancer. 2027 will be a critical year, and the company is expected to submit ZOCI's first biological product marketing license application (BLA) in the US.

It is worth noting that previously, Zaiding Pharmaceutical announced at the ESMO 2026 conference the first data from a global phase Ib clinical study of Zoci combined with atilizumab (with or without carboplatin) for first-line treatment of extensive small cell lung cancer (ES-SCLC). Investment bank Cantor released a research report stating that the data published by Zaiding DLL3 ADC zoci in first-line widespread small-cell lung cancer has reached the “Home Run (home run)” level. Thoracic oncologists at New York University Grossman School of Medicine who also participated in the discussion are optimistic that zoci will replace first-line chemotherapy, which has the potential to change the first-line treatment pattern and gradually grow into a cornerstone treatment for small cell lung cancer.